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Abstract
Background: The contribution of birth defects, including cleft lip and palate, to neonatal and infant mortality and 
morbidity is substantial. As other mortality and morbidity causes including infections, hygiene, prematurity, and 
nutrition are eradicated in less developed countries, the burden of birth defects will increase proportionally.
Methods/Design: We are using cleft lip and palate as a sentinel birth defect to evaluate its burden on neonatal 
and infant health and to assess the effectiveness of systematic pediatric care during the first month and first two 
years of life in decreasing this burden. The neonatal intervention, consisting of weekly pediatric evaluation and 
referral to appropriate care, is delivered to about 696 infants born with cleft lip and/or palate in 47 hospitals in 
South America. Neonatal mortality in this group will be compared to that in a retrospective control group of 
about 464 infants born with cleft lip and/or palate in the same hospitals. The subgroup of infants with isolated 
clefts of both the lip and palate (about 264) is also randomized into two groups, intervened and non-intervened, 
and further followed up over 2 years. Intervened cases are evaluated by pediatricians every three months and 
referred for appropriate care. The intervened and non-intervened cases will be compared over study outcomes 
to evaluate the intervention effectiveness. Non-intervened cases are matched and compared to healthy controls 
to assess the burden of cleft lip and palate. Outcomes include child's neurological and physical development and 
family social and economic conditions.
Discussion: Large-scale clinical trials to improve infant health in developing countries are commonly suggested, 
making it important to share the methods used in ongoing studies with other investigators implementing similar
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research. We describe here the content of our ongoing pediatric care study in South America. We hope that this 
may help researchers targeting this area to plan their studies more effectively and encourage the development of 
similar research efforts to target other birth defects or infant outcomes such as prematurity and low birth weight.
Background
Neonatal and infant mortality and morbidity are high in 
less developed countries. Each year about 10 million chil­
dren die worldwide, with extensive between and within 
country variation [1,2], Almost half of these deaths (about 
4 million) occur among newborns before one month of 
age [2-4], The majority (about95%) of all neonatal deaths 
occur in less developed countries, where 34 neonates die 
among every 1000 live births, compared to 5 neonates in 
developed countries [3,4]. In the past two decades, greater 
reductions have been observed in child mortality than in 
neonatal mortality with the lowest reductions observed in 
the early neonatal phase [4], leading to a greater number 
of deaths within the first month of life.
Among the main causes of neonatal mortality in develop­
ing countries (infections, prematurity complications, and 
birth asphyxia), congenital anomalies constitute the 
fourth leading cause, and are responsible for about 7- 
10% and 3.8% of neonatal and under - 5 mortality, 
respectively [1,3,4]. Congenital malformations are 
increasingly contributing to overall infant mortality in 
developed countries such as the United States [5], where 
20% of infant deaths in 2001 were related to congenital 
malformations [6]. The burden of birth defects will also 
be expected to increase in developing countries as public 
health, nutrition, and other primary health interventions 
succeed in reducing main mortality and morbidity causes 
such as infections and low birth weight. Besides mortality, 
birth defects also increase the risk for disability. In 2002, 
more than T1 million lost Disability Adjusted Life Years 
(DALYs) forming about 1.8% of the overall burden of dis­
ease were related to congenital abnormalities [1].
Oral clefts are common birth defects that affect about 1 in 
every 700 births with varying prevalence by population 
origin and socioeconomic status [7,8]. Cleft lip and palate 
occurs as both isolated and syndromic forms [9]. Isolated 
forms are unassociated with any other structural or cogni­
tive birth defects. Syndromic forms of clefts have a wide 
range of etiologies with more than 400 reported in Online 
Mendelian Inherited Diseases in Man [10] from single 
gene causes and with other clefts occurring secondary to 
chromosomal anomalies, teratogenic exposures, and as 
sporadic disorders without recognized etiologies.
Isolated forms are readily targeted by care provided by 
multi-specialty teams yet may still have substantial infant 
morbidity and mortality specifically in cases with limited 
access to care that might include for example, education 
for appropriate feeding. Malnourishment of infants bom 
with clefts because of feeding problems may enhance the 
impact of other mortality risk factors such as infections. A 
few studies have reported several-fold increased neonatal 
and infant mortality risks among infants born with clefts, 
specifically among syndromic forms [11-13]. Further, 
there is evidence of a long-term burden even of isolated 
forms, mainly in challenges for psychological and social 
adjustment [14-16] as well as reduced life expectancy 
[17].
Since clefts are readily apparent at birth, they can serve as 
sentinels for other birth defects and their impact. We are 
studying cleft lip and palate as a model birth defect to 
determine whether an increased pediatric care model can 
decrease mortality and morbidity in an infant population 
bom in-hospital mainly to indigent populations in South 
America. The primary research aims include evaluating if 
neonatal mortality among children born with cleft lip 
and/or cleft palate can be decreased by a systematic pedi­
atric intervention over the first month of life, and if sys­
tematic pediatric care over the first two years of life can 
improve the neurodevelopment and growth of children 
bom with isolated forms of cleft lip with cleft palate com­
pared to usual pediatric care. The neurodevelopment and 
growth of this latter group will also be compared to those 
of healthy control babies without birth defects receiving 
usual pediatric care. Secondary research aims include eval­
uating the effectiveness of the pediatric intervention and 
follow-up program on other neonatal and two-year of life 
health outcomes, which are described below in further 
detail.
The study benefits from a well-established consortium of 
pediatricians working under the auspices of the Estudio 
Colaborativo Latino Americano de Malformaciones Con- 
genitas (ECLAMC), a birth defects surveillance program 
that has been active in South America since 1967 [18]. 
Currendy, about 80 hospitals are enrolled in ECLAMC 
and carry out surveillance of birth defects on approxi­
mately 200,000 births per year. We used this infrastruc­
ture to identify pediatricians who could provide direct 
care to infants bom with cleft lip and palate and follow 
them closely for the first month to ensure that appropriate 
medical and surgical interventions were undertaken. The 
impact of systematic pediatric care throughout the first 
two years of life on health is also being studied in the sub­
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group with isolated cleft lip and cleft palate using the 
same infrastructure.
The objectives of this paper include reporting how the 
project was established and describing study design and 
interventions. There has been increased emphasis recendy 
for establishing large-scale clinical trials to study perinatal 
and neonatal health interventions in less developed coun­
tries. Recent study reviews have identified the need for 
more clinical trials to address several research gaps in the 
provision of neonatal care in these settings [19,20]. Fur­
ther evaluation of the effectiveness of alternative models 
for neonatal care content and delivery is one emphasized 
theme. Yet litde empirical guidance on how to optimally 
design and implement these trials in less developed coun­
tries is available. As more resources are being allocated 
into this field, it is important to share methods of ongoing 
large-scale interventional trials. This may help researchers 
plan their studies to appropriately adjust interventions, 
improve procedures, and estimate adequate budgets. We 
hope that sharing our study methods would be of direct 
relevance to researchers and funding agencies targeting 
this area.
Methods/Design
Setting and participants
Study participants are being recruited in 47 ECLAMC hos­
pitals from 35 cities in Argentina, Brazil, Bolivia, Chile, 
Colombia, Ecuador and Venezuela (see list in acknowl­
edgements section). Study participants include live born 
infants with cleft lip and/or palate and healthy infants and 
their parents. Infants with a typical oral cleft as the only 
detected congenital anomaly are considered isolated 
cases. Infants with atypical oral clefts (oblique facial clefts, 
congenital healed clefts, midline cleft lip, submucous cleft 
palate, bifid uvula) are excluded. In this study, syndromic 
forms of cleft lip and palate include cases with recognized 
syndromes, cases with chromosome abnormalities, cases 
with one or more major structural anomalies other than 
cleft lip and palate, cases with cognitive delay (IQ or 
equivalent less than 80), or cases exposed to recognized 
teratogens in utero (phenytoin or valproic acid). Cases 
born to mothers who smoked or used alcohol during 
pregnancy who otherwise do not meet the syndromic 
form criteria listed above are considered isolated cases. 
Syndromes are classified using chromosomal analysis 
and/or by physical findings, and all cases are reviewed by 
at least two experienced dysmorphologists [Eduardo Cas­
tilla, Monica Ritder, Viviana Cosentino, Iêda Orioli, jeff 
Murray].
Indusion/exdusion criteria
The neonatal prospective group that receives the pediatric 
intervention includes infants bom with typical clefts of 
any etiology or affected segment (lip, gum, hard palate, 
soft palate) in participating hospitals between january, 
2003 and December, 2005, and diagnosed as eligible 
within the first 48 hours after birth, with an initially pro­
jected total of about 696 cases to be available for recruit­
ment. No other inclusion or exclusion criteria are 
imposed on this group. Since it was considered unethical 
to randomize neonatal subjects into treatment and no 
treatment control groups, as there was a strong sentiment 
that the intervention forms the current standard of care in 
the United States, a retrospective control group born in 
2001 and 2002 with clefts in the same hospitals was cho­
sen. This control group is projected to include about 464 
cases, yet data are still being processed. This group of 
infants had previously received routine pediatric and 
medical care offered by their communities during the neo­
natal period. A schema of the study design is shown in Fig­
ure 1.
The two-year study group includes children from the neo­
natal prospective subgroup who are born with isolated 
forms of both cleft lip and cleft palate. Children with syn­
dromic forms are excluded, as are twins and children with 
birth weight less than 2500 grams or who have complica­
tions other than cleft lip and palate that require systematic 
care. A group of healthy controls born without birth 
defects and subject to the same exclusion criteria and 
whose gestational age is between 37 and 42 weeks are also 
included in the two-year study.
Neonatal intervention
The neonatal intervention in the prospective group 
involves weekly monitoring and evaluation of infant 
health through follow up visits to participating ECLAMC 
pediatricians. The visits usually occur at the hospital of 
birth or private offices of participating pediatricians; visits 
to subjects' homes are encouraged when the weekly visits 
are missed. During each of the four neonatal visits extend­
ing to one month of age, the pediatrician conducts a clin­
ical assessment of infant health and growth. Special 
emphasis is placed on weight gain, feeding problems, and 
medical complications such as hyperbilirubinemia or 
infection. The pediatrician also interviews parents for 
family and household factors that may affect the infant 
health. Based on assessment results, the pediatrician refers 
the infant to appropriate health professionals for special­
ized care. Recommendations and instructions to parents 
regarding infant needs and optimal care are also provided. 
If the child demonstrates a failure to gain weight, physi­
cians will, using standard medical judgment, determine 
whether hospital admission is appropriate or whether the 
child can be sent home. If sent home, the infant may be 
followed at more frequent intervals depending on the 
severity of the weight loss or other medical complications. 
Any decrease in weight by greater than 10 percent will 
require hospital admission and weight decreases between
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Neonatal Subproject
Figure I
Study Design. Figure I presents a flowchart of the study design of the neonatal and the two-year subprojects. All infants born 
with a typical form of cleft lip and palate in the study hospitals are enrolled in the neonatal subproject. Only isolated cases with 
both cleft of lip and cleft palate who are singleton births, normal birth weight, and without complications other than cleft lip 
and palate that require systematic care are enrolled at birth in the two-year subproject and randomized into intervened and 
non-intervened groups. A group of healthy controls is matched to the non-intervened group by gender, date and hospital of 
birth at a ratio of 2 to I. A = Evaluating the impact of the intervention on neonatal mortality. BI = Evaluating the impacts of 
cleft lip and palate on child's development and family socioeconomic outcomes (Two-year subproject). B2 = Evaluating the 
impact of the two-year intervention on child development and family socioeconomic outcomes.
0 and 10 percent will have suitability for admission deter- The impact of the pediatric intervention on neonatal mor- 
mined by the referring physician. tality will be assessed by comparing mortality rates
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between the retrospective and prospective study groups. 
Birth time periods for the two groups are close and consec­
utive, limiting time changes in conditions such as quality 
of health care that may affect mortality and confound the 
evaluation of the intervention's impact.
ECLAMC started in 2001 a program tided "ORIENT" to 
provide guidance prior to hospital discharge to parents of 
infants bom with birth defects about appropriate care and 
available treatments for the infant [18]. The retrospective 
group has also received this standard of care available at 
ECLAMC hospitals in addition to the standard of care 
available in the community.
Two-year intervention
A second intervention is being carried out on a subset of 
children with isolated cleft lip with cleft palate, with an 
initially projected total of about 264 cases to be available 
for this subproject. Screening for eligibility and enroll­
ment into the two-year subproject occurs at birth. Eligible 
children with clefts are randomized at birth into inter­
vened or non-intervened groups. The pediatricians con­
duct a thorough clinical assessment of the development of 
intervened children every three months up to two years of 
age, including evaluation of physical growth (height, 
weight, and head circumference), neurodevelopment, 
using the Bayley Infant Neurodevelopmental Screener 
(BINS), and language, using the Receptive-Expressive 
Emergent Language Test (REEL). The BINS is used to mon­
itor the course of an infant's development and identifies 
infants with developmental delays or neurological 
impairments who are in need of further diagnostic evalu­
ation [21,22], The REEL screens for delays in emergent 
speech and language development in medically and envi­
ronmentally at-risk children [23,24]. The pediatricians 
also perform a dental assessment for the child and record 
erupted teeth and any abnormalities, check the nutri­
tional status including feeding content, process, and prob­
lems, and inquire about all child morbidities and 
treatments since the last evaluation and overall changes in 
health and socioeconomics of family members (e.g. 
parental illnesses, changes in employment and marital 
status of the parents, and changes in schooling and health 
status of siblings). The pediatricians refer the intervened 
children to specialized health facilities and professionals 
based on their clinical assessments and the practice stand­
ards available for dealing with clefts and emphasize to 
parents the importance of compliance with these referrals. 
The pediatricians also provide counseling to parents in 
order to maintain a healthy and loving familial environ­
ment that provides continuous care to the child.
The healthy control children enrolled in the two-year 
study as a normal control group are matched to the non­
intervened cleft group two to one at birth for sex, hospital, 
and week of birth. The non-intervened control group of 
children with clefts and the healthy control group receive 
the standard of care available in their respective commu­
nity according to parental wishes. Both control groups are 
assessed at one and two-year follow-ups to measure study 
outcomes. The normal control group will be compared to 
the non-intervened cases with clefts to assess the impact of 
clefting on child health and family socioeconomic out­
comes. The intervened and non-intervened cases with 
clefts will be compared to evaluate the effectiveness of the 
intervention in lowering the burden of clefting on the 
child and the family (see Figure 1).
Randomization procedures in the two-year study
The randomization of cases in the two-year study into 
intervened and non-intervened groups is based on a ran­
domization sequence generated by the Data Center at the 
Research Triangle Institute (RH) International, and is 
stratified by participating hospitals. The Data Center pro­
vides each pediatrician a set of sealed envelopes that con­
tain a sheet indicating treatment assignment. The 
pediatrician administers the randomization procedure by 
assigning the next available envelope as each case is 
enrolled into the study. Study personnel and subjects are 
not blinded to the randomization assignments, but safe­
guards are in place to ensure that assignments are not 
known a priori. The pediatrician reports within 24 hours 
of each randomization to the Data Center the subject ID, 
the tracking number of the randomization envelope used, 
and the group assignment for verification, and any incon­
sistencies are readily corrected. The randomization 
sequence lists are kept in secure locations at the Data 
Center and ECLAMC headquarters.
Study outcomes
The neonatal outcomes include overall mortality at 28 
days of life (primary outcome), mortality in subgroups of 
isolated and non-isolated cleft groups, hospitalization 
days, and refinement of syndromic classification in the 
retrospective group. The impact of the neonatal interven­
tion on infant mortality will also be evaluated and phone 
interviews are conducted with parents of prospective and 
retrospective groups when needed to inquire about child's 
survival at one year of age. The primary outcomes of the 
two-year study include overall neurodevelopment (meas­
ured by BINS) and weight changes. Secondary outcomes 
include performance on four ability areas including neu­
rological functions/intactness, receptive functions, expres­
sive functions, and cognitive processes (measured by the 
BINS), speech (measured by REEL), height changes, hear­
ing, timing of cleft surgery, mortality, refinement in syn­
dromic status classification, and emotional, social, and 
economic performance of the family.
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Power analysis
The power analyses prepared prior to study initiation are 
reported in Tables 1 and 2 for the neonatal and the two- 
year subprojects respectively. The power estimation for 
the primary hypothesis of reduction in neonatal mortality 
in the prospective group compared to the retrospective 
control group assumes a simple random sample scheme 
and a probability of Type I error of 0.05. Power is esti­
mated for alternative neonatal mortality rates in both the 
prospective and retrospective control groups due to the 
lack of robust estimates at the time of study initiation of 
baseline mortality rates in the retrospective group and of 
potential achievable reductions in neonatal mortality due 
to the intervention. Mortality rates of 20, 25, and 30% are 
assumed for the retrospective group. The neonatal mortal­
ity rate in the prospective group is also assumed to not 
exceed 25% and to be not higher than that of the retro­
spective group (one-sided test). The power calculation for 
the neonatal subproject is based on a sample size of 464 
cases in the retrospective group and 696 cases in the pro­
spective group. This analysis shows that acceptable power 
(>0.7) is available for reductions of about 30% or more in 
assumed baseline neonatal mortality rates (See Table 1).
The power analysis to detect differences in means of the 
continuous outcomes of the two-year study (e.g. BINS and 
REEL scores or weight gain) between the study groups is 
also based on alternative effect sizes due to limited infor­
mation available a priori on these parameters and on 
alternative sample sizes. In this analysis, power estimation 
assumes a paired sample where one subject is selected at 
random and another is a matched control (correlation of 
0.5 between the subjects in a matched pair). Power is eval­
uated for standardized effect sizes (i.e. mean difference 
divided by standard deviation) of 0.15, 0.25, 0.4, and 0.5, 
using a Type I error probability of 0.05 and a one sided 
test. The analysis shows that acceptable power (>0.7) is 
available to detect a standardized effect size of 0.25 or 
higher with a sample size of 90 cases per study group. As 
an example, a 0.25 standardized effect size for the recep­
tive language quotient of the REEL measure is equivalent 
to a 4-point difference from a mean score of 108 with a 
standard deviation of 16, which are reference estimates for 
samples of normal babies under 36 months of age.
Statistical analysis
The effects of the pediatric interventions on the studied 
outcomes will be analyzed using simple statistical tests for 
comparisons between intervened and control groups as 
well as multivariate regression techniques that account for 
potential confounders between the evaluated groups such 
as cleft type, baseline health characteristics, family socioe­
conomic status, and for sample clustering across hospitals 
and countries of birth. Logistic regression and Cox-pro­
portional hazard models will be used to evaluate differ­
ences in overall neonatal mortality between the 
prospective and retrospective groups as well as in sub­
groups of isolated and non-isolated clefts. Similarly, 
weight changes and other developmental (e.g. BINS, 
REEL, height, etc.) and socioeconomic outcomes (e.g. 
maternal employment) will also be compared between 
the intervened and non-intervened cleft groups on one 
side and between the non-intervened cleft group and the 
healthy control group on another side using regression 
analyses. Correlation among subjects recruited within the 
same hospital (within hospital clustering) and within- 
subject correlation in analyses involving multiple obser­
vations per subject will be accounted for by using hierar- 
chical/mixed models or Generalized Estimating 
Equations (GEE) methods or by applying robust estima­
tors for the variance-covariance of regression parameters. 
Country indicators will be included as covariates in mul­
tiple country analyses. Further analyses will also evaluate 
differences in primary characteristics (e.g. cleft type, birth 
weight) between subjects retained in the study and those 
who drop out and further adjustment for participation 
propensity will be applied if real differences emerge.
Table I: Power to Detect Differences in Neonatal Mortality Proportions
Neonatal Mortality in Retrospective Group Neonatal Mortality in Prospective Group Power
0.20 0.12 0.97
0.15 0.68
0.17 0.34
0.25 0.15 0.99
0.17 0.94
0.20 0.61
0.22 0.30
0.30 0.15 >0.99
0.17 >0.99
0.2 >0.99
0.22 0.98
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Table 2: Power to Detect Differences in Means of Continuous 
Outcomes in the Two-Year Study
Sample Size per Group Standardized Effect Size
0.15 0.25 0.4 0.5
60 0.30 0.60 0.92 0.98
90 0.40 0.76 0.98 >0.99
120 0.49 0.85 >0.99 >0.99
150 0.55 0.91 >0.99 >0.99
160 0.59 0.93 >0.99 >0.99
170 0.61 0.94 >0.99 >0.99
Data collection and management
ECLAMC maintains birth records on all participants 
[18,25]. Updated data on the retrospective group is col­
lected through abstraction of medical records and through 
phone or home interviews of parents. The pediatricians 
collect data for the prospective group at birth and at the 
periodic follow up evaluations in the neonatal and two- 
year subprojects. Specific data collection forms and out­
come measures were developed for the purposes of this 
study. Samples of data forms are available from the 
authors on request. Data are entered into personal digital 
assistants (PDAs) in a system designed and implemented 
by the Global Network for Women's and Children's 
Health Research Data Coordinating Center at RTI. Data 
are transferred on a routine basis from participating hos­
pitals to the study database server in Buenos Aires, and 
then to RTI via the Internet in a secure, encrypted file with 
personal identifiers stripped. RTI routinely reports to the 
National Institute of Child Health and Development 
(NICHD) appointed Data Monitoring Committee that 
oversees study progress and outcomes.
Personnel training
In order to prepare the pediatricians from ECLAMC for 
participation in the study, training sessions were carried 
out mosdy in conjunction with the annual ECLAMC 
meetings. In addition to study design and procedures, 
focused training was provided for the use of PDAs for data 
collection and for administration of the developmental 
instruments (BINS and REEL). Both the BINS and the 
REEL were instruments not commonly used in South 
America. Following approval from the commercial pro­
viders, both were translated and back translated into 
Spanish and Portuguese. A three-day instructional semi­
nar on the use of the BINS and REEL included power point 
presentations, training videotapes, practice sessions and 
written instructions. These instruments were enthusiasti­
cally received by participating pediatricians and there 
have been few concerns expressed over their implementa­
tion. We are currendy using English language norms for 
comparison but are working on developing both Spanish 
and Portuguese versions of the BINS. Training in the use
Table 3: Study Pediatricians
Responsible professional City Country
Rittler, Monica Buenos Aires Argentina
Rottenberg, Daniela Buenos Aires Argentina
Cosentino, Viviana Buenos Aires Argentina
Jewtuszyk, Monica Buenos Aires Argentina
Lerner, Mario Gualeguaychú Argentina
Mussi, Margarita Rosario Argentina
Ermini, Monica La Piata Argentina
Cárpena, Luisa Cordoba Argentina
Chirino, Andrea Cordoba Argentina
Echegaray, Adriana Cordoba Argentina
Negri, Carlos San Martin Argentina
Menzio, Monica San Luis Argentina
Sáleme, César Tucumán Argentina
Deguer, Carlos Bahia Bianca Argentina
Lombardelli, Rodolfo Esquel Argentina
Mereb, Juan Carlos El Bolsón Argentina
Rueda, Saúl La Paz Bolivia
Nogueira, Aurea Fiori anópolis Brazil
Canonaco, Rosane Sao Paulo Brazil
Leite, Julio César Porto Alegre Brazil
Cavalcanti, Denise Campinas Brazil
Ternes-Pereira, Eliana Fiori anópolis Brazil
Abath, Cristina Joao Pessoa Brazil
Acosta, Angelina Salvador Brazil
Nazer-Herrera, Julio Santiago Chile
Ojeda, Maria Elena Rancagua Chile
Canessa, Aurora Linares Chile
Wettig, Elisabeth Puerto Montt Chile
Mellado, Cecilia Santiago Chile
Farfan, Victor Talca Chile
Diaz, Marcela Santiago Chile
Zarante, Ignacio Bogotá Colombia
Garcia, Natalia Bogotá Colombia
Villegas, Carlos A. Man Ízales Colombia
Luna Ballén, Ana M. La Mesa Colombia
Cristancho, Camilo U bâté Colombia
Montalvo, Germán Quito Ecuador
Toscano, Mario Manabi Ecuador
Girón, Cecibel Manabi Ecuador
Camacho, Antonio 1barra Ecuador
Sacoto, Adriana Cañar Ecuador
Martinez, Ernesto Azogues Ecuador
Cedeño, Rosa Maracaibo Venezuela
Jatar Senior, Braulio Coro Venezuela
of the PDAs as well as in methods of electronic data trans­
fer provided individualized tutoring in software/hardware 
use based on the needs and experience of each individual. 
Retraining is carried out on an annual basis with a pri­
mary focus on new and updated procedures.
Informed consents
Signed informed consent protocols were established after 
several iterations with local, Iowa, and RTI Institutional 
Review Boards (IRBs) that included translations and back 
translations from Spanish and Portuguese to English. Sep­
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arate signed informed consents are being utilized for the 
neonatal and two-year subprojects among the prospective 
group. In case of illiteracy, ECLAMC pediatricians read the 
informed consent and fully explain its content to the 
mother or legal guardian of the eligible infant. Confirma­
tion is obtained via thumbprints in this case in the pres­
ence of a witness. For the retrospective data collection, 
verbal consent is obtained from the parent or legal guard­
ian for participation.
Discussion
This paper describes the methods of a study that is evalu­
ating the effectiveness of a model of care that pediatri­
cians, even in difficult settings, may provide to improve 
survival and health of children bom with birth defects. We 
believe it is important to document the feasibility of con­
ducting international collaborative clinical trials aimed at 
prevention and treatment of craniofacial anomalies and 
other anomalies as strategies to decrease the global bur­
den imposed by birth defects. The intervention in this 
project is consistent with recommendations of the Insti­
tute of Medicine (IOM) to reduce the impact of birth 
defects in the developing world by providing better treat­
ments for affected children [26]. The IOM report high­
lights the importance of early thorough assessments to 
better identify existing anomalies and define the treat­
ment plans for children with birth defects.
Isolated forms of oral clefts pose larger risks for morbidity 
and challenged development than for mortality among 
affected infants and children. It is therefore expected that 
the pediatric intervention may be more effective in 
improving these outcomes than in reducing the mortality 
risk in this group.
This study is readily expandable to include infants born 
with other potentially lethal anomalies that can benefit 
from early recognition and referral. Neural tube defects 
and congenital heart disease would be among the com­
mon non-cleft birth defects where early intervention may 
prove life saving until appropriate surgical or medical care 
can be completed. Furthermore, this intervention may be 
studied among infants bom preterm and/or at low birth 
weight. Up to 28% of worldwide neonatal deaths are 
attributed to prematurity, and up to 80% of neonatal 
deaths occur among children bom at low birth weight 
[3,4], a highly prevalent condition specifically in develop­
ing countries where 16% of live births are underweight 
[27], forming about 95% of worldwide underweight 
births. Other prevention based approaches such as the 
folic acid food fortification program in Chile that has 
decreased neural tube defects by at least 30% in the last 
three years [28] should be used in conjunction with pro­
grams like the one described here that addresses the needs 
of infants born with birth defects.
The study is being successfully implemented using the 
preexisting infrastructure of the ECLAMC birth defects 
surveillance program. The study implementation strate­
gies have a relatively low cost as they rely on an existing 
infrastructure and a group of dedicated physicians and 
their colleagues. This approach will easily be transporta­
ble to other sites and hypotheses. In future studies we 
hope to include parents of affected children as members 
of peer support groups. They can serve as physician 
extenders to enhance attendance at interventional and fol­
low-up visits and to sustain the intervention in the com­
munity if it proves to be effective. Since the studied 
interventions are of tolerable cost and use existing person­
nel, the long-term prospects are good for continuing and 
expanding these research efforts.
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